Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XECHEM (ZKEM)- Drugs from nature? -- Ignore unavailable to you. Want to Upgrade?

To: Kincheloe who wrote (5)	2/23/1999 12:47:00 PM
From: thomas a. burke	Read Replies (1) \| Respond to of 24

I see this thread has been VERY quiet. Could this news from last month have anything to do with todays heavy volume? Tuesday January 26, 11:04 am Eastern Time Company Press Release Xechem Announces Issuance of U.S. Patent No. 5,840,930 for Method for Production of Novel Dihalocephalomannines NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 26, 1999--Xechem International, Inc. (OTC BB: ZKEM - news) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 5,840,930 containing broad coverage for methods for production of 2'', 3''-dihalocephalomannine compounds which are designated as second generation to the well-known anticancer drug paclitaxel. This will be the sixth patent in this important area granted to Xechem. Xechem's new compounds have been shown to have significant anticancer activities against a wide array of tumors in preliminary studies. According to Xechem's President and CEO, Dr. Ramesh Pandey, ''We are extremely excited about the prospects of our paclitaxel analogs. Preliminary laboratory data has shown that these compounds may be more effective than paclitaxel or Taxotere® in treating certain tumor cell lines, and are more physiologically soluble, thus potentially offering viable alternatives to paclitaxel without its dangerous side effects. With the exclusivity afforded by a newly issued patent, we hope to develop unique products of choice in this burgeoning area of the market.'' Xechem is a bio-pharmaceutical company engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of difficult to replicate anticancer, antiviral (including AIDS) and antifungal compounds. The Company also screens compounds for therapeutic action from China and India. For further information, contact Xechem's President and Chief Executive Officer, Dr. Ramesh C. Pandey (732) 247 - 3300. This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements. Contact: Xechem International President and Chief Executive Officer Dr.Ramesh C. Pandey , 732/247-3300 More Quotes and News: Xechem International Inc (OTC BB:ZKEM - news) Related News Categories: biotech, medical/pharmaceutical